Final results from phase II study of volociximab, an α5ß1 anti-integrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC) Meeting Abstract
| Authors: | Yazji, S.; Bukowski, R.; Kondagunta, V.; Figlin, R. |
| Abstract Title: | Final results from phase II study of volociximab, an α5ß1 anti-integrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC) |
| Meeting Title: | 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 25 |
| Issue: | 18 Suppl. |
| Meeting Dates: | 2007 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2007-06-20 |
| Start Page: | 258s |
| Language: | English |
| ACCESSION: | WOS:000455043701222 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2007.25.18_suppl.5094 |
| Notes: | Meeting Abstract: 5094 -- Source: Wos |
